EXECUTIVE ENGAGEMENTS
POOL
913
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
183
Interactions with Platform & by Email
PARTICIPANTS
37
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
33
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
22
PAGES
89
EDITION
6
PRICE
USD 5600
CODE
MCP22954
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Tissue Engineered Skin Substitutes estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 8.2% over the analysis period 2020-2027. Biological, one of the segments analyzed in the report, is projected to record a 8.8% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Synthetic segment is readjusted to a revised 8% CAGR for the next 7-year period.
The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$633 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$645.8 Million by the year 2027 trailing a CAGR of 7.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.6% and 6.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.
In the global Biosynthetic segment, USA, Canada, Japan, China and Europe will drive the 6.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$258.2 Million in the year 2020 will reach a projected size of US$407.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$428.4 Million by the year 2027.
SELECT PLAYERS
Amarantus Bioscience Holdings, Inc.; BSN medical; ConvaTec Group PLC; Integra LifeSciences Corporation; Kerecis; LifeNet Health; Mallinckrodt; Medline Industries, Inc.; MiMedx; Mölnlycke Health Care AB; Organogenesis Inc.; Regenicin; Smith & Nephew; Tissue Regenix
SEGMENTS
» Product (Biological, Synthetic, Biosynthetic) » Application (Acute, Chronic) » End-Use (Hospitals, Wound Care Centers, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Biosynthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Biosynthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Acute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Acute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Wound Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Wound Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| USA Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| USA Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| China Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| China Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| France Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| France Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| UK Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| UK Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 33 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com